Pharmacologic use of Niacin

Journal of Evidence-Based Complementary and Alternative Medicine

Volumn 16, Issue 1, 2011, Pages 91-101

  Prousky, Jonathan ^a   Millman, Christine G ^b   Kirkland, James B ^c  

^a CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^b University of Guelph ^*

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

Depression; Dyslipidemia; Lipid metabolism; Migraine; Niacin; Niacinamide; Pellagra

Indexed keywords

EID: 79957941119     PISSN: 21565872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Carpenter KJ. Pellagra. Stroudsburg, PA: Hutchinson Ross; 1981.
2. Goldberger J. The relation of diet to pellagra. JAMA. 1922;78: 1676-1680.
3. Elvehjem CA, Madden RJ, Strong FM, Woolley DM. Relation of nicotinic acid and nicotinic acid amide to canine black tongue. J Am Chem Soc. 1937;59:1767-1768.
4. Kirkland JB. Niacin. In: Rucker R, Zempleni J, Suttie JW, McCormick DB, eds. Handbook of Vitamins. 4th ed. New York, NY: Taylor & Francis; 2007:191-232.
5. Kirkland JB. Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des. 2009;15:3-11.
6. Kirkland JB. Poly ADP-ribose polymerase-1 and health. Exp Biol Med (Maywood). 2010;235:561-568.
7. Li D, Sun WP, Zhou YM, et al. Chronic niacin overload may be involved in the increased prevalence of obesity in US children. World J Gastroenterol. 2010;16:2378-2387.
8. Jacobson EL. Niacin deficiency and cancer in women. J Am Coll Nutr. 1993;12:412-416.
9. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002;75:616-658.
10. Ruffin JM, Smith DT. Effect of sunlight on the clinical manifestations of pellagra. Arch Intern Med. 1937;59:631-645.
11. Serdaru M, Hausser-Hauw C, Laplane D, et al. The clinical spectrum of alcoholic pellagra encephalopathy. A retrospective analysis of 22 cases studied pathologically. Brain. 1988;111(pt 4):829-842.
12. Pitsavas S, Andreou C, Bascialla F, Bozikas VP, Karavatos A. Pellagra encephalopathy following B-complex vitamin treatment without niacin. Int J Psychiatry Med. 2004;34:91-95.
13. Spivak JL, Jackson DL. Pellagra: an analysis of 18 patients and a review of the literature. Johns Hopkins Med J. 1977;140: 295-309.
14. Prousky JE. Pellagra may be a rare secondary complication of anorexia nervosa: a systematic review of the literature. Altern Med Rev. 2003;8:180-185.
15. Monteiro JP, da Cunha DF, Filho DC, et al. Niacin metabolite excretion in alcoholic pellagra and AIDS patients with and without diarrhea. Nutrition. 2004;20:778-782.
16. Desgroseilliers JP, Shiffman NJ. Pellagra. Can Med Assoc J. 1976;115:768-770.
17. Inculet RI, Norton JA, Nichoalds GE, Maher MM, White DE, Brennan MF. Water-soluble vitamins in cancer patients on parent-eral nutrition: a prospective study. JPEN J Parenter Enteral Nutr. 1987;11:243-249.
18. Dreizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad Med. 1990;87:163-167.
19. Stevens HP, Ostlere LS, Begent RH, Dooley JS, Rustin MH. Pellagra secondary to 5-fluorouracil. Br J Dermatol. 1993;128: 578-580.
20. Bender DA. Biochemistry of tryptophan in health and disease. Mol Aspects Med. 1983;6:101-197.
21. Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol. 2005;100:2307-2314.
22. McCabe-Sellers BJ, Sharkey JR, Browne BA. Diuretic medication therapy use and low thiamin intake in homebound older adults. J Nutr Elder. 2005;24:57-71.
23. Paulionis L, Kane SL, Meckling KA. Vitamin status and cognitive function in a long-term care population. BMC Geriatr. 2005;5:16.
24. Fu CS, Swendseid ME, Jacob RA, McKee RW. Biochemical markers for assessment of niacin status in young men: levels of ery-throcyte niacin coenzymes and plasma tryptophan. J Nutr. 1989;119:1949-1955.
25. Barthelemy H, Chouvet B, Cambazard F. Skin and mucosal manifestations in vitamin deficiency. J Am Acad Dermatol. 1986;15: 1263-1274.
26. Harris S. Clinical Pellagra. St Louis, MO: CV Mosby; 1941.
27. Hauw JJ, De Baecque C, Hausser-Hauw C, Serdaru M. Chroma-tolysis in alcoholic encephalopathies. Pellagra-like changes in 22 cases. Brain. 1988;111(pt 4):843-857.
28. Sydenstricker VP. The neurological complications of malnutrition: I-psychic manifestations of nicotinic acid deficiency. Proc R Soc Med. 1943;36:169-171.
29. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol. Arch Biochem. 1955;54:558-559.
30. Brooks EL, Kuvin JT, Karas RH. Niacin's role in the statin era. Expert Opin Pharmacother. 2010;11:2291-2300.
31. Miller M. Niacin as a component of combination therapy for dys-lipidemia. Mayo Clin Proc. 2003;78:735-742.
32. Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J Am Coll Cardiol. 2008;51:56-58.
33. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007;357:1009-1017.
34. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994; 271:672-677.
35. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721-2726.
36. Fazio S, Guyton JR, Polis AB, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol.
37. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol. 1987;2:10-32.
38. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993;92:78-82.
39. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353-361.
40. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
41. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005; 115:3634-3640.
42. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000;284:1263-1270.
43. Soudijn W, van Wijngaarden I, Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med Res Rev. 2007;27:417-433.
44. Watts GF, Chan DC. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism. Arterioscler Thromb Vasc Biol. 2008;28:1892-1895.
45. Trueblood NA, Ramasamy R, Wang LF, Schaefer S. Niacin protects the isolated heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2000;279:H764-H771.
46. Datta S, Das DK, Engelman RM, et al. Enhanced myocardial preservation by nicotinic acid, an antilipolytic compound: mechanism of action. Basic Res Cardiol. 1989;84:63-76.
47. Kirkland JB. Niacin status and treatment-related leukemogenesis. Mol Cancer Ther. 2009;8:725-732.
48. Boyonoski AC, Gallacher LM, ApSimon MM, et al. Niacin deficiency in rats increases the severity of ethylnitrosourea-induced anemia and leukopenia. J Nutr. 2000;130:1102-1107.
49. Spronck JC, Nickerson JL, Kirkland JB. Niacin deficiency alters p53 expression and impairs etoposide-induced cell cycle arrest and apoptosis in rat bone marrow cells. Nutr Cancer. 2007;57: 88-99.
50. Kostecki LM, Thomas M, Linford G, et al. Niacin deficiency delays DNA excision repair and increases spontaneous and nitrosourea-induced chromosomal instability in rat bone marrow. Mutat Res. 2007;625:50-61.
51. Bartleman AP, Jacobs R, Kirkland JB. Niacin supplementation decreases the incidence of alkylation-induced nonlymphocytic leukemia in Long-Evans rats. Nutr Cancer. 2008;60:251-258.
52. Lawless SC, Verma P, Green DM, Mahoney MC. Mortality experiences among 15{thorn} year survivors of childhood and adolescent cancers. Pediatr Blood Cancer. 2007;48:333-338.
53. Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer. 2009;115:23-35.
54. Hoskin P, Rojas A, Saunders M. Accelerated Radiotherapy, car-bogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a phase ii nonrandomized study. Int J Radiat Oncol Biol Phys. 2009;73:1425-1431.
55. Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull. 2007;30:367-370.
56. Benemei S, Nicoletti P, Capone JG, De Cesaris F, Geppetti P. Migraine. Handb Exp Pharmacol. 2009;(194):75-89.
57. Nardone R, Tezzon F. The trigemino-cervical reflex in tension-type headache. Eur J Neurol. 2003;10:307-312.
58. Hannerz J, Jogestrand T. Relationship between chronic tension-type headache, cranial hemodynamics, and cerebrospinal pressure: study involving provocation with sumatriptan. Headache. 2004;44:154-159.
59. Cady R, Schreiber C, Farmer K, Sheftell F. Primary headaches: a convergence hypothesis. Headache. 2002;42:204-216.
60. Prousky J, Seely D. The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature. Nutr J. 2005;4:3.
61. Atkinson M. Migraine headache: some clinical observations on the vascular mechanism and its control. Ann Intern Med. 1944; 21:990-997.
62. Goldzieher JW, Popkin GL. Treatment of headache with intravenous sodium nicotinate. J Am Med Assoc. 1946;131:103-105.
63. Grenfell RF. Treatment of migraine with nicotinic acid. Am Pract Dig Treat. 1949;3:542-544.
64. Grenfell RF. Treatment of tension headache. Am Pract Dig Treat. 1951;2:933-936.
65. Morgan ZR. Nicotinic acid therapy in vasoconstriction type of headache. Md State Med J. 1953;2:377-382.
66. Morgan ZR. A newer method of nicotinic acid therapy in headache of the vasoconstrictive type. J Am Geriatr Soc. 1955;3:545-551.
67. Hall JA. Enhancing niacin's effects for migraine. Cortlandt Forum. 1991;46:47.
68. Prousky J, Sykes E. Two case reports on the treatment of acute migraine with niacin. Its hypothetical mechanism of action upon calcitonin-gene related peptide and platelets. J Orthomol Med. 2003;18:108-110.
69. Velling DA, Dodick DW, Muir JJ. Sustained-release niacin for prevention of migraine headache. Mayo Clin Proc. 2003;78: 770-771.
70. Morrow JD, Parsons WG III, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38:263-274.
71. Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992;98: 812-815.
72. Bicknell F, Prescott F. The Vitamins in Medicine. 3rd ed. Milwaukee, WI: Life Foundation for Nutritional Research; 1953.
73. Jordaan B, Oliver DW, Dormehl IC, Hugo N. Cerebral blood flow effects of piracetam, pentifylline, and nicotinic acid in the baboon model compared with the known effect of acetazolamide. Arznei-mittelforschung. 1996;46:844-847.
74. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol. 2004;7:193-218.
75. Ishizaki J, Yamamoto H, Takahashi T, Takeda M, Yano M, Mimura M. Changes in regional cerebral blood flow following antidepressant treatment in late-life depression. Int J Geriatr Psychiatry. 2008;23:805-811.
76. Lemke H, de Castro AG, Schlattmann P, Heuser I, Neu P. Cerebrovascular reactivity over time-course-from major depressive episode to remission. J Psychiatr Res. 2010;44:132-136.
77. Washburne AC. Nicotinic acid in the treatment of certain depressed states; a preliminary report. Ann Intern Med. 1950;32:261-269.
78. Tonge WL. Nicotinic acid in the treatment of depression. Ann Intern Med. 1953;38:551-553.
79. Thompson LJ, Proctor RC. Depressive and anxiety reactions treated with nicotinic acid and phenobarbital. N C Med J. 1953; 14:420-426.
80. MacSweeney DA. Letter: Treatment of unipolar depression. Lancet. 1975;2:510-511.
81. Chouinard G, Young SN, Annable L, Sourkes TL, Kiriakos RZ. Tryptophan-nicotinamide combination in the treatment of newly admitted depressed patients. Commun Psychopharmacol. 1978; 2:311-317.
82. Chouinard G, Young SN, Annable L, Sourkes TL. Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study. Acta Psychiatr Scand. 1979;59:395-414.
83. Badawy AA, Evans M. Letter: Tryptophan plus a pyrrolase inhibitor for depression. Lancet. 1975;2:869.
84. Lin SH, Chong ZZ, Maiese K. Nicotinamide: a nutritional supplement that provides protection against neuronal and vascular injury. J Med Food. 2001;4:27-38.
85. Oxenkrug GF. Metabolic syndrome, age-associated neuroendo-crine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci. 2010;1199:1-14.
86. Coyle JT, Balu D, Benneyworth M, Basu A, Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci. 2010;12: 359-382.
87. Hoffer A. The adrenochrome theory of schizophrenia: a review. Dis Nerv Syst. 1964;25:173-178.
88. Smythies J. Endogenous neurotoxins relevant to schizophrenia. J R Soc Med. 1996;89:679-680.
89. Smythies JR. Oxidative reactions and schizophrenia: a review-discussion. Schizophr Res. 1997;24:357-364.
90. Smythies J. The adrenochrome hypothesis of schizophrenia revisited. Neurotox Res. 2002;4:147-150.
91. Hoffer A. Niacin Therapy in Psychiatry. Springfield, IL: Charles C. Thomas; 1962.
92. Hoffer A. Megavitamin B-3 therapy for schizophrenia. Can Psychiatr Assoc J. 1971;16:499-504.
93. Petrie WM, Ban TA. Vitamins in psychiatry. Do they have a role? Drugs. 1985;30:58-65.
94. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006;1073-1074:25-37.
95. Miller CL, Dulay JR. The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. Brain Res Bull. 2008;77:33-41.
96. Shah GM, Le Rhun Y, Sutarjono I, Kirkland JB. Niacin deficient SKH-1 mice are more susceptible to ultraviolet B radiation-induced skin carcinogenesis. J Nutr. 2001;131(11 suppl):3150S.
97. Gensler HL, Williams T, Huang AC, Jacobson EL. Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr Cancer. 1999;34:36-41.
98. Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids. 2010;2010:157591.
99. Benavente CA, Jacobson MK, Jacobson EL. NAD in skin: therapeutic approaches for niacin. Curr Pharm Des. 2009;15: 29-38.
100. Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol. 1995;34:434-437.
101. Niren NM. Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review. Cutis. 2006; 77(1 suppl):11-16.
102. Laws HW. Peripheral vasodilators in the treatment of macular degenerative changes in the eye. Can Med Assoc J. 1964;91: 325-330.
103. Hannan F, Davoren P. Use of nicotinic acid in the management of recurrent hypoglycemic episodes in diabetes. Diabetes Care. 2001;24:1301.
104. Earthman TP, Odom L, Mullins CA. Lactic acidosis associated with high-dose niacin therapy. South Med J. 1991;84:496-497.
105. Baggenstoss AH, Christensen NA, Berge KG, Baldus WP, Spiekerman RE, Ellefson RD. Fine structural changes in the liver in hypercholesteremic patients receiving long-term nicoti-nic acid therapy. Mayo Clin Proc. 1967;42:385-399.
106. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol. 1995;79:54-56.
107. Tittler EH, de Barros DS, Navarro JB, et al. Oral niacin can increase intraocular pressure. Ophthalmic Surg Lasers Imaging. 2008;39:341-342.
108. Barakat MR, Metelitsina TI, DuPont JC, Grunwald JE. Effect of niacin on retinal vascular diameter in patients with age-related macular degeneration. Curr Eye Res. 2006;31:629-634.